Diego Salas-Benito, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1105 | 0.570 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 1041 | 0.380 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 4648 | 0.330 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2024 | 1757 | 0.320 |
Why?
|
| Pancreatic Neoplasms | 3 | 2024 | 5446 | 0.320 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2024 | 1512 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 8647 | 0.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 5432 | 0.230 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 4916 | 0.220 |
Why?
|
| GPI-Linked Proteins | 1 | 2024 | 472 | 0.200 |
Why?
|
| Neoplasms | 4 | 2023 | 22371 | 0.180 |
Why?
|
| Endopeptidases | 1 | 2024 | 764 | 0.170 |
Why?
|
| Platinum | 1 | 2020 | 222 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 3611 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 13586 | 0.150 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 13676 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 1406 | 0.140 |
Why?
|
| Nuts | 1 | 2019 | 264 | 0.140 |
Why?
|
| Drug Synergism | 1 | 2021 | 1760 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2024 | 1982 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 1901 | 0.110 |
Why?
|
| Immunotherapy | 2 | 2020 | 4755 | 0.110 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 10266 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 6316 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 3948 | 0.090 |
Why?
|
| Apoptosis | 1 | 2024 | 9523 | 0.070 |
Why?
|
| Vaccination | 1 | 2019 | 3437 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 8054 | 0.060 |
Why?
|
| Phenotype | 1 | 2021 | 16726 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2024 | 412 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
| Prognosis | 2 | 2021 | 30010 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 39348 | 0.050 |
Why?
|
| Humans | 11 | 2024 | 768166 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 17140 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 5703 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2023 | 1009 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2024 | 1027 | 0.040 |
Why?
|
| Spain | 1 | 2020 | 485 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2023 | 840 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2021 | 81762 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 1996 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 2568 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2017 | 559 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 4528 | 0.020 |
Why?
|
| Mutation | 1 | 2016 | 30238 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2024 | 5151 | 0.020 |
Why?
|
| Mice | 3 | 2024 | 82029 | 0.020 |
Why?
|
| Patient Selection | 1 | 2020 | 4260 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 4120 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2024 | 7876 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 6395 | 0.020 |
Why?
|
| Animals | 3 | 2024 | 169246 | 0.020 |
Why?
|
| Female | 2 | 2021 | 397192 | 0.010 |
Why?
|
| Telemedicine | 1 | 2020 | 3109 | 0.010 |
Why?
|
| Survival Rate | 1 | 2016 | 12840 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 11244 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 5341 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8748 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2020 | 24315 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22379 | 0.010 |
Why?
|
| Middle Aged | 1 | 2016 | 223492 | 0.000 |
Why?
|
| Male | 1 | 2016 | 364719 | 0.000 |
Why?
|